InterMune to Present at the 2008 Wachovia Healthcare ...( BRISBANE Calif. Jan. 23 /- InterM...),Health
Navigation Links
InterMune to Present at the 2008 Wachovia Healthcare Conference
Date:1/23/2008
BRISBANE, Calif., Jan. 23 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that Steven Porter, M.D., Ph.D., Chief Medical Officer of InterMune, will present at the 2008 Wachovia Healthcare Conference in Boston on January 31, 2008 at 10:15 a.m. EST.
To access a live audio webcast of the presentation, investors and other interested parties may log on to the investor relations page of InterMune's corporate website at http://www.intermune.com. The company recommends logging on to the site 15 minutes prior to the start of the presentation in order to register or download any necessary software.
About InterMune
InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has a pipeline portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes the Phase 3 program, CAPACITY, which is evaluating pirfenidone as a possible therapeutic candidate for the treatment of patients with IPF and a research program focused on small molecules for pulmonary disease. The hepatology portfolio includes the HCV protease inhibitor compound ITMN-191 (R7227) in Phase 1b, a second-generation HCV protease inhibitor research program, and a research program evaluating a new target in hepatology. For additional information about InterMune and its R&D pipeline, please visit http://www.intermune.com.
Forward-Looking Statements
Except for the historical information contained herein, this press
release contains certain forward-looking statement
'/>"/>
| SOURCE InterMune, Inc. Copyright©2008 PR Newswire. All rights reserved |
Related medicine news :
1. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
2. AtriCure to Present at Thomas Weisel Partners 2007 Healthcare Conference
3. Matrixx Initiatives, Inc. to Present at the Roth Capital Partners 2007 New York Conference
4. BD to Present at the Bear Stearns 20th Annual Healthcare Conference
5. ATS Medical to Present at the 2007 Thomas Weisel Partners Healthcare Conference
6. Omnicell to Present at Thomas Weisel Healthcare Conference 2007
7. AtriCure to Present at Roth Capital Partners 2007 New York Conference
8. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
9. MDS to Present at Thomas Weisel Partners Healthcare Conference
10. Hospira to Present at the Bear Stearns 20th Annual Healthcare Conference on September 11
11. AMICAS to Present at Thomas Weisel Partners Healthcare Conference 2007
Post Your Comments:
(Date:11/26/2009)..., NEWYORK,Nov.27/PRNewswire/--Withcoldandflus...racticestocontrolthespreadofinfectionsandavoidilln...veshealthy,buttoavoidtransmittingillnessifwe,resic...n-control),nursingdirectorforinfectioncontrolandoc...Manhattan. ,, HospitalforSpecialSurgeryhasoneof...
(Date:11/26/2009)... In the next 25 years, the number of Americans liv...rom 23.7 million in 2009 to 44.1 million in 2034. ...most triple, rising from $113 billion to $336 bill...esity, researchers based at the University of Chic... . , The number of those with diabetes covered b...
(Date:11/26/2009)...uggage that,s too big or too heavy can lead to str...lthDay News) -- There may be nothing wrong with st... not want to do the same thing with your suitcase ...00 people were treated in 2008 in U.S. hospital em... medical facilities for luggage-related injuries, ...
(Date:11/26/2009)... No more letters from the ...,personalized text messages from Santa , ...fort to increase operational efficiencies at the N... to help keep children all over the globe informed...Elves in Santa’s research department have id...
(Date:11/26/2009)... Research Triangle Dental ...tral North Carolina, today announced the expansion...ed LUMINEER Dentist, Dr. Doug Macmillan. , ...h Triangle Dental is pleased to announce that Dr. ..., recently completed an additional advanced traini...
Breaking Medicine News(10 mins):Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 2Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 3Health News:Diabetes cases to double and costs to triple by 2034 2Health News:Diabetes cases to double and costs to triple by 2034 3Health News:Pack Right for the Holidays to Avoid the ER 2Health News:Text Messages from Santa | Santa goes GREEN by going MOBILE for The March of Dimes 2Health News:Dr. Douglas Macmillan Now Providing LUMINEERS at Research Triangle Dental 2[1] Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use[0] Diabetes cases to double and costs to triple by 2034[2] Pack Right for the Holidays to Avoid the ER[1] Text Messages from Santa | Santa goes GREEN by going MOBILE for The March of Dimes[0] Dr. Douglas Macmillan Now Providing LUMINEERS at Research Triangle Dental
...(Nasdaq: MNKD ), focused on discovering, developi... cancer, announced today that it,will present at t...h 17,2008 at 3:15 PM ET at the Marriott Copley Pla...ny,s website at, http://www.mannkindcorp.com . A r...
...17 Citi Conference, CHICAGO, March 13 Brookdale ...hat management will make a presentation,regarding ...onference on,Wednesday, March 19, 2008 at 9:00 a.m...ons section of the Company,s website at, http://ww...
... traditional metal stents , , THURSDAY, Ma... quietly absorbed by the body after it has done it... well in an international trial, researchers repor...able stent had been implanted had closed again. On...
...care & Medicaid Services (CMS) today released a ne...ressure (CPAP) therapy for Medicare patients,with ...ciaries will be able,to undergo diagnosis for OSA ... American Academy,of Sleep Medicine (AASM), the le...
...millions of older adults, safety advocates and hea... $20.7 million for the,Centers for Disease Control...-scale problem of falls among older Americans., E... 1.8 million older adults were treated in emergenc...
...enosine linked to priapism , Priapism (prolonged...) is common in male individuals with sickle cell d...normally shaped red blood cells. Priapism is consi...ubsequently, erectile dysfunction and impotence. H...
Other Medicine News:Health News:Brookdale to Present at Lehman Global Healthcare Conference on March 19 2Health News:Melt-Away Stent Works Well in Trial 2Health News:Melt-Away Stent Works Well in Trial 3Health News:30 National Organizations Issue Call to Action for Congress to Fully Fund Falls Prevention Programming in CDC Budget 2Health News:30 National Organizations Issue Call to Action for Congress to Fully Fund Falls Prevention Programming in CDC Budget 3Health News:JCI online early table of contents: March 13, 2008 2Health News:JCI online early table of contents: March 13, 2008 3Health News:JCI online early table of contents: March 13, 2008 4Health News:JCI online early table of contents: March 13, 2008 5Health News:JCI online early table of contents: March 13, 2008 6Health News:JCI online early table of contents: March 13, 2008 7MannKind to Present at the Cowen and Company Healthcare ConferenceBrookdale to Present at Lehman Global Healthcare Conference on March 19Melt-Away Stent Works Well in TrialCMS Approves Home Sleep Testing for Diagnosis of OSA; AASM Experts Available for Comment30 National Organizations Issue Call to Action for Congress to Fully Fund Falls Prevention Programming in CDC BudgetJCI online early table of contents: March 13, 2008
(Date:11/26/2009)...ESBURG,SouthAfrica,Nov.26/PRNewswire/--The2009Fros...eGenericPharmaceuticalMarketispresentedtoCiplaMedp...com.com/cgi-bin/prnh/20081117/FSLOGO ) ,, Forth...dtobenchmarkCiplaMedpro,sperformanceagainstkeycomp...novationinbusinessprocesses,productsand/ortechnolo...
(Date:11/25/2009)...D,Mass.,Nov.25/PRNewswire-FirstCall/--Hologic,Inc....oper,manufacturerandsupplierofpremiumdiagnostics,m...servingthehealthcareneedsofwomen,isusingtheannualm...atMcCormickPlaceinChicago,November29throughDecembe...dalitydiagnosticmammographyworkstationsoftware. ,...
(Date:11/25/2009)...Pa.,Nov.25/PRNewswire/--BioTrendsResearchGroup,Inc... report,thefirstinamulti-phasesyndicatedmarketrese...h,sStelara,fromproductlaunchthroughthefirstsixmont...tativeinformationfrom75uniqueDermatologistsandqual...trialanduseofStelara,obstaclestouse,typicalpatient...
Breaking Medicine Technology:Frost & Sullivan Award Underlines Cipla Medpro's Status as Company of the Year in the South African Generic Pharmaceutical Market 2Frost & Sullivan Award Underlines Cipla Medpro's Status as Company of the Year in the South African Generic Pharmaceutical Market 3New Hologic SecurView(R) DX Diagnostic Workstation Software Streamlines Workflow, Improves Radiologist Productivity 2New Hologic SecurView(R) DX Diagnostic Workstation Software Streamlines Workflow, Improves Radiologist Productivity 3Despite Managed Care Obstacles, Interest and Anticipated Use of Centocor Ortho-Biotech's New Psoriasis Agent Stelara (ustekinumab) is High 2Research reveals exactly how coughing is triggered by environmental irritants 10862 1Research reveals exactly how coughing is triggered by environmental irritants 10862 2Lose the fat 3A Targeting grease to curtail sewer overflows 10859 1Lose the fat 3A Targeting grease to curtail sewer overflows 10859 2Sporicidin Brand Disinfectant Kills H1N1 in 3 Minutes 14943 1Sporicidin Brand Disinfectant Kills H1N1 in 3 Minutes 14943 2[0] Frost & Sullivan Award Underlines Cipla Medpro's Status as Company of the Year in the South African Generic Pharmaceutical Market[0] New Hologic SecurView(R) DX Diagnostic Workstation Software Streamlines Workflow, Improves Radiologist Productivity[0] Despite Managed Care Obstacles, Interest and Anticipated Use of Centocor Ortho-Biotech's New Psoriasis Agent Stelara (ustekinumab) is High
...irst Approved Systemic Therapy to Treat the Diseas...,Bayer HealthCare Pharmaceuticals and Onyx Pharmac... The New England Journal of Medicine published,res...(R) (sorafenib),tablets decreased the absolute ris...able hepatocellular carcinoma (HCC), or liver canc...
...23 Sound Pharmaceuticals (SPI) has filed,an Inves...he clinical,testing of a proprietary formulation o...ed hearing loss or ototoxicity. The oral capsule,c...anced stage lung cancer,and head and neck cancer p...s marks the second development program for SPI to ...
Other Medicine Technology:The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 2The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 3The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 4The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 5The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 6Sound Pharmaceuticals Files Second IND with the FDA for the Prevention of Chemotherapy Induced Hearing Loss in Advanced Stage Cancer 2Avant® 9700
Resolve® Immersion Oil
Immersion Oil, 150 cs
Immersion oil for microscopy
Medicine Products:| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |